Canaccord Genuity Group Issues Pessimistic Forecast for Compass Pathways (NASDAQ:CMPS) Stock Price

Compass Pathways (NASDAQ:CMPS) had its target price cut by Canaccord Genuity Group from $20.00 to $18.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Canaccord Genuity Group’s target price points to a potential upside of 235.20% from the stock’s current price.

A number of other brokerages have also commented on CMPS. Morgan Stanley decreased their target price on Compass Pathways from $18.00 to $16.00 and set an “overweight” rating for the company in a research report on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Compass Pathways in a report on Wednesday, January 21st. Royal Bank Of Canada raised their price objective on Compass Pathways from $21.00 to $22.00 and gave the company an “outperform” rating in a research note on Wednesday, February 18th. Lifesci Capital upgraded Compass Pathways to a “strong-buy” rating in a report on Thursday, February 12th. Finally, HC Wainwright upped their target price on Compass Pathways from $40.00 to $70.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $21.63.

Compass Pathways Stock Down 4.8%

Shares of NASDAQ CMPS opened at $5.37 on Thursday. The company has a quick ratio of 1.23, a current ratio of 0.77 and a debt-to-equity ratio of 0.55. The firm has a market cap of $515.63 million, a PE ratio of -1.74 and a beta of 1.90. The company’s fifty day simple moving average is $6.66 and its 200 day simple moving average is $6.30. Compass Pathways has a 12-month low of $2.25 and a 12-month high of $8.90.

Compass Pathways (NASDAQ:CMPS) last posted its quarterly earnings results on Tuesday, March 24th. The company reported ($1.00) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.59). As a group, sell-side analysts forecast that Compass Pathways will post -2.33 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Compass Pathways

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Toronto Dominion Bank boosted its stake in Compass Pathways by 152.9% during the 4th quarter. Toronto Dominion Bank now owns 2,529,013 shares of the company’s stock valued at $17,447,000 after purchasing an additional 1,529,013 shares during the last quarter. Jefferies Financial Group Inc. bought a new stake in Compass Pathways during the 3rd quarter worth approximately $7,890,000. Nantahala Capital Management LLC raised its stake in shares of Compass Pathways by 47.7% in the second quarter. Nantahala Capital Management LLC now owns 4,179,930 shares of the company’s stock worth $11,704,000 after purchasing an additional 1,350,698 shares during the last quarter. Ameriprise Financial Inc. bought a new position in shares of Compass Pathways in the third quarter valued at approximately $6,926,000. Finally, Hsbc Holdings PLC purchased a new position in shares of Compass Pathways during the second quarter valued at approximately $3,011,000. Institutional investors and hedge funds own 46.19% of the company’s stock.

More Compass Pathways News

Here are the key news stories impacting Compass Pathways this week:

• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating with a very high $70 price target, signaling a strong long‑term bullish case and large implied upside versus the current share price. (This supports investor optimism even as near‑term forecasts were adjusted.)
• Neutral Sentiment: Upcoming FDA review meeting for COMP360 is a potential binary catalyst — outcomes or guidance from that meeting could swing sentiment materially in either direction. Compass Pathways (CMPS): What will come out of FDA review meeting for depression drug candidate COMP360?
• Neutral Sentiment: Canaccord cut its price target from $20 to $18 but kept a “Buy” rating — a modest downgrade that still implies significant upside from current levels. Canaccord target cut report
• Negative Sentiment: HC Wainwright lowered its FY2026 EPS forecast to ($1.66) from ($1.36) and cut FY2027 to ($0.96) (previously $0.72), and issued lower quarterly EPS estimates across 2026–2027 — firms’ reduced profit outlook increases short‑term pressure on the share price.
• Negative Sentiment: Morgan Stanley trimmed its price target to $16, which reduces near‑term upside and may prompt short‑term selling. Morgan Stanley Lowers Compass Pathways (NASDAQ:CMPS) Price Target to $16.00
• Negative Sentiment: Recent earnings (reported 3/24) missed estimates (EPS -$1.00 vs. consensus -$0.41), reinforcing concerns on near‑term profitability and contributing to downward pressure on the stock.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.